Ennovabio
- Company typePrivate
- Founded2018
- HeadquartersShanghai, China
- Headcount251–500
- GTM typeB2B
- OfferingServices
What Ennovabio does
Ennovabio (轶诺药业, formally Shanghai Ennovabio Pharmaceutical Co., Ltd.) is a clinical-stage biopharmaceutical company headquartered in Shanghai's Pudong New Area, founded in 2018 by Dr. Jiang Lei (CEO) and Dr. Shou Jianyong (CSO), with additional senior leadership including Dr. Shang Ke (Biology VP), Dr. Zhang Jianhua (BD Head), Dr. Li Qian (Senior Analytics Director), and part-time CMO Dr. Peng Bin appointed in October 2023. The company focuses on developing first-in-class therapeutics for autoimmune diseases, diabetic complications, chronic inflammation, and cancer, with 6 distinct projects spanning preclinical and clinical stages. Its core technology is the proprietary eSTEM Systems Biology Platform, which integrates bioinformatics, systems biology, and machine learning/deep learning to identify and prioritize novel, traditionally 'undruggable' drug targets in autoimmune, inflammatory, and metabolic diseases.
Ennovabio operates internal drug discovery capabilities spanning target assessment, medicinal chemistry, in vitro/in vivo pharmacology, CMC, DMPK, and clinical development. The company has expanded into nucleic-acid modalities via a strategic co-development partnership with Darui Biopharma (announced January 12, 2023) to develop first-in-class siRNA therapeutics for metabolic liver diseases (NAFLD, NASH, fibrosis) using Darui's RAZOR platform alongside Ennovabio's target assessment capabilities. As of October 2025, the company was recognized as one of six winners in Bayer China's inaugural 'Co-Create New Drugs' competition for excellence in autoimmune, chronic inflammation, and metabolic complications research.
The company's revenue model is pre-commercial and based on future drug development and commercialization, with current income (if any) tied to licensing or co-development rather than product sales; pricing details are not publicly disclosed. Its go-to-market motion combines enterprise-level partnership and co-development with Big Pharma and biotech partners (Bayer, Darui Biopharma) alongside innovation competitions, scientific conferences, and academic engagement to build pipeline visibility. Capital sources to date include Series 1 funding of $10M led by Highlight Capital and Zhangke Lingyi Investment (2017), a $14M Series 2 led by Matrix Partners China (2019), a Series 2 extension led by Shanghai Biomedical Industrial Equity Investment Fund (2021), and a 2025 round with participation from K&C Capital, Shanghai Kangcheng Investment Management, and Zhangke Lingyi Investment.
Ennovabio firmographics
Firmographics- Name
- Ennovabio
- Legal name
- 上海轶诺药业有限公司
- Website
- https://ennovabio.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
Ennovabio industry classification
Industry- Product category
- Drug Discovery & Development
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)
Keywords
Where Ennovabio is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices1 record
Markets served
Ennovabio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure
Revenue model
- Drug Development and Commercialization: Clinical-stage biopharmaceutical company developing first-in-class therapeutics for autoimmune diseases, diabetic complications, and cancer. Revenue model is pre-commercial; pipeline assets are in preclinical and clinical development stages across 6 distinct projects.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Ennovabio product offering
Product offeringCore offering
Ennovabio is a clinical-stage biopharmaceutical company that discovers and develops first-in-class therapeutics for autoimmune diseases, diabetic complications, cancer, and metabolic liver diseases. The company uses its proprietary eSTEM Systems Biology Platform, which integrates systems biology with machine learning and deep learning, to identify and prioritize novel drug targets. Its pipeline comprises 6 distinct projects spanning preclinical and clinical development, with internal capabilities covering target assessment, medicinal chemistry, pharmacology, CMC, DMPK, and clinical development.
Product overview
Ennovabio (轶诺药业) is a clinical-stage biopharmaceutical company focused on first-in-class drug discovery for autoimmune diseases, diabetic complications, and cancer. The company operates its proprietary eSTEM Systems Biology Platform for target identification and drug discovery, supporting a pipeline of 6 projects spanning preclinical to clinical development stages. The company also develops siRNA therapeutics for liver diseases through strategic partnerships.
Differentiator
Problem solved
Functional benefit
Products and services
- eSTEM Systems Biology Platform
Companies that use Ennovabio
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles1 record
Ennovabio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Ennovabio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Darui Biopharma (大睿生物医药科技有限公司)coreEnnovabio and Darui Biopharma entered into a strategic partnership to co-develop first-in-class siRNA therapeutics for metabolic liver diseases. Ennovabio contributes target assessment capabilities and drug discovery expertise in metabolic diseases through its eSTEM platform; Darui Biopharma contributes its proprietary RAZOR™ next-generation siRNA platform for discovering siRNA lead compounds targeting liver-protective and function-improving novel targets. The partnership aims to develop treatments for 'undruggable' targets in fatty liver disease, NASH, and liver fibrosis — conditions with no effective pharmacological treatments currently available.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Ennovabio competitors and assessment
Company assessmentDirect peers
- XtalPi: Chinese AI-driven drug discovery company combining physics-based modeling, quantum mechanics, and ML to identify novel drug candidates; comparable in applying AI/ML to early-stage discovery and target prioritization, with a similar first-in-class discovery orientation.
- Abbisko Therapeutics: Chinese clinical-stage biotech focused on precision oncology and small-molecule therapeutics; comparable as a venture-backed Shanghai-based clinical-stage biotech with similar pipeline breadth and licensing/partnering orientation.
- Rona Therapeutics (Darui Biopharma): Strategic co-development partner of Ennovabio for siRNA-based metabolic liver disease therapeutics; a Chinese clinical-stage biotech using a proprietary next-generation siRNA platform (RAZOR™) to target metabolic, renal, CNS, and ophthalmologic diseases — directly comparable modality and disease-area overlap.
- Elpiscience Biopharmaceuticals: Chinese clinical-stage biotech developing innovative immunotherapies for cancer and autoimmune/inflammatory diseases; comparable in Chinese clinical-stage biotech profile and similar focus on immune-mediated disease areas.
Emerging players
- Insitro: US-based AI/ML-driven drug discovery company using machine learning and high-throughput biology to discover therapeutics, with focus on metabolic and neurological disease; comparable in AI-enabled target ID approach but at later stage and broader therapeutic footprint.
- Recursion Pharmaceuticals: US-based AI-driven drug discovery company combining high-throughput experimental biology with machine learning across multiple therapeutic areas; comparable in using AI/ML as a platform to systematically generate first-in-class candidates.
- Schrödinger: US-based computational drug discovery platform combining physics-based simulation with ML for hit identification, lead optimization, and target evaluation; comparable in applying computational/AI methods to accelerate small-molecule discovery.
Broad incumbents
- BeiGene: Major global Chinese-origin biopharmaceutical company with a broad pipeline across oncology and immunology; comparable as a large Chinese-founded biotech with first-in-class ambitions, though at far greater scale and with multiple commercialized products.
- Junshi Biosciences: Leading Chinese innovation-driven biopharmaceutical company developing first-in-class biologics and small molecules across oncology, autoimmune, and metabolic disease; comparable as a Chinese clinical-stage-to-commercial biotech pursuing innovative targets in overlapping disease areas.
- Innovent Biologics: Larger Chinese biopharmaceutical company developing innovative medicines across oncology, autoimmune, and metabolic disease with multiple approved and clinical-stage assets; comparable in therapeutic-area overlap (autoimmune, metabolic) but at significantly more advanced commercialization stage.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Ennovabio social profiles
Digital presenceEnnovabio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ennovabio leadership team
Management profileNumber of profiles
Profiles6 records
Ennovabio funding detail
Funding detailFunding overview
Funding rounds4 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ennovabio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ennovabio
What does Ennovabio do?
Ennovabio is a clinical-stage biopharmaceutical company that discovers and develops first-in-class therapeutics for autoimmune diseases, diabetic complications, cancer, and metabolic liver diseases. The company uses its proprietary eSTEM Systems Biology Platform, which integrates systems biology with machine learning and deep learning, to identify and prioritize novel drug targets. Its pipeline comprises 6 distinct projects spanning preclinical and clinical development, with internal capabilities covering target assessment, medicinal chemistry, pharmacology, CMC, DMPK, and clinical development.
Is Ennovabio a public or private company?
Ennovabio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ennovabio founded?
Ennovabio was founded in 2018. It employs 251 to 500 people.
Where is Ennovabio based?
Ennovabio is headquartered in Shanghai, China, in the Asia region.
How does Ennovabio make money?
One revenue line is on record: drug Development and Commercialization.
Who are Ennovabio's main competitors?
Direct peers on record are XtalPi, Abbisko Therapeutics, Rona Therapeutics (Darui Biopharma) and Elpiscience Biopharmaceuticals. Emerging players are Insitro, Recursion Pharmaceuticals and Schrödinger. Broad incumbents are BeiGene, Junshi Biosciences and Innovent Biologics.
Does Ennovabio have an API?
No public API is recorded for Ennovabio.
What industry is Ennovabio in?
Ennovabio's product category is Drug Discovery & Development. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 541714 and its SIC code is 2834.